MYC and neoplasm: Notably, while HPV frequency, age, gender, and tumor stage at diagnosis were not different between the two groups (Supplementary Table 3), the 5-year overall survival of patients with MYC amplified tumors was lower compared to the MYC wild-type counterparts (Fig. 3d), supporting the relevance of the molecular landscape changes described above to patient’s outcomes.